Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-08-01 9:18 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | SAMLYN CAPITAL LLC | 6,263,758 9.990% | -4,226 (-0.07%) | View |
| 2024-05-13 4:52 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | SAMLYN CAPITAL LLC | 6,267,984 9.990% | 3,771,725 (+151.10%) | View |
| 2024-05-09 5:29 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | Point72 Asset Management L.P. | 17,050,384 9.900% | 17,050,384 (New Position) | View |
| 2024-05-08 7:55 pm Unchanged | 13D | CORVUS PHARMACEUTICALS INC CRVS | ORBIMED ADVISORS LLC | 6,943,654 11.100% | 0 (Unchanged) | View |
| 2024-02-14 1:31 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | SAMLYN CAPITAL LLC | 2,496,259 5.100% | 2,496,259 (New Position) | View |
| 2024-02-13 6:27 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | MILLER RICHARD A MD | 3,684,010 7.190% | 578,889 (+18.64%) | View |
| 2023-02-14 4:00 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | TANG CAPITAL PARTNERS LP | 0 0.000% | -3,101,709 (Position Closed) | View |
| 2023-02-13 12:01 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | CHI Advisors LLC | 2,384,402 5.120% | 2,384,402 (New Position) | View |
| 2023-02-10 4:00 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | MILLER RICHARD A MD | 3,105,121 6.450% | 497,973 (+19.10%) | View |
| 2023-01-30 4:17 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | INTEGRATED CORE STRATEGIES (US) LLC | 1,899,516 4.100% | -1,020,543 (-34.95%) | View |
| 2022-02-14 4:15 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | Venrock Healthcare Capital Partners II L.P. | 250,000 0.500% | -3,177,461 (-92.71%) | View |
| 2022-02-14 4:00 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | TANG CAPITAL PARTNERS LP | 3,101,709 6.700% | 3,101,709 (New Position) | View |
| 2022-02-11 7:30 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | BIOTECHNOLOGY VALUE FUND L P | 1,370,947 3.000% | -1,527,850 (-52.71%) | View |
| 2022-02-11 5:55 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | MILLER RICHARD A MD | 2,607,148 5.450% | 427,589 (+19.62%) | View |
| 2022-01-18 4:55 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | INTEGRATED CORE STRATEGIES (US) LLC | 2,920,059 6.300% | 403,531 (+16.04%) | View |
| 2021-12-06 4:44 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | INTEGRATED CORE STRATEGIES (US) LLC | 2,516,528 5.400% | 487,927 (+24.05%) | View |
| 2021-11-03 3:03 pm Unchanged | 13D | CORVUS PHARMACEUTICALS INC CRVS | ORBIMED ADVISORS LLC | 6,943,654 14.900% | 0 (Unchanged) | View |
| 2021-10-22 4:36 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | INTEGRATED CORE STRATEGIES (US) LLC | 2,028,601 4.800% | 2,028,601 (New Position) | View |
| 2021-10-05 1:03 pm Sale | 13G | CORVUS PHARMACEUTICALS INC CRVS | EcoR1 Capital LLC | 81,077 0.200% | -5,000,000 (-98.40%) | View |
| 2021-09-30 4:05 pm Purchase | 13G | CORVUS PHARMACEUTICALS INC CRVS | Venrock Healthcare Capital Partners II L.P. | 3,427,461 8.100% | 3,427,461 (New Position) | View |